August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Mario Balsa: A PI3K Path Worth Walking – If You Can Manage the Steps
Jul 13, 2025, 13:57

Mario Balsa: A PI3K Path Worth Walking – If You Can Manage the Steps

Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared a post on X:

INAVO120 (NEJM): In PIK3CA-mutated, HR+/HER2– endocrine-resistant MBC, inavolisib + palbociclib + fulvestrant vs placebo:

  • mOS: 34.0 vs 27.0 mo (HR 0.67; p=0.02)
  • Higher AEs: 6.8% d/c due to toxicity

A PI3K path worth walking – if you can manage the steps.

Congrats to Komal Jhaveri and all the team!”

Title: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

Journal: NEJM

Authors: Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner

Read the full article.

Mario Balsa

More posts featuring Mario Balsa on OncoDaily.